Upsher-Smith/Unigene Suit Over Fortical Triggers 30-Month Stay Of Apotex' ANDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Product approved under 505(b)(2) now faces encroachment through traditional generic pathway.